Clinical Trials on rrMM in United Kingdom
Total 13 results
-
Oncopeptides ABTerminatedRRMMBulgaria, United States, Czechia, Hungary, Ukraine
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Spain, Australia, Brazil, United Kingdom, Poland, Taiwan, Singapore, France, Italy
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis | RRMSSpain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
-
BayerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
-
Regeneron PharmaceuticalsActive, not recruitingRelapsed and Refractory Multiple Myeloma (RRMM)United States
-
TakedaTerminatedRelapsed and/or Refractory Multiple Myeloma (RRMM)United States, Canada
-
National Cancer Institute (NCI)RecruitingMultiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)United States
-
EMD SeronoPfizerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)United States
-
Icahn School of Medicine at Mount SinaiWithdrawnRelapsing-remitting Multiple Sclerosis (RRMS)United States
-
BiogenAbbVieTerminatedRelapsing-Remitting Multiple Sclerosis (RRMS)Italy, United States, Canada, Germany, Puerto Rico
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
GenmabRecruitingAcute Myeloid Leukemia (AML) | Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Multiple Myeloma (RRMM)United States, Korea, Republic of, Netherlands, Denmark, Australia, New Zealand, Poland, Spain, Sweden, Czechia, Malaysia, Greece, Moldova, Republic of, Georgia, Ukraine, France, Hungary, North Macedonia, Bosnia and Herzegovina
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China